US4781601046 - Common Stock
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.
The Nasdaq and S&P 500 tumbled below their 50-day lines.
This is what could happen next to Johnson & Johnson shares.
NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron are included in this Analyst Blog.
A Florida jury on Thursday concluded that Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a Florida woman who died in 2019. The lawsuit was brought by family members of Patricia Matthey, a Sarasota County resident who used Johnson's baby powder daily from 1965 until August 2016, when she was diagnosed with ovarian cancer, according to her family's lawsuit. J&J's Worldwide Vice President of Litigation Erik Haas said the company was vindicated by the jury's decision.
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).
Discover recession-proof stocks that thrive amid economic uncertainty, offering stability and consistent growth.
Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder.
Although monetary policy seemed to be moving in a dovish direction, a pivot may warrant a look at stocks for Fed hikes.
In market uncertainty, dividend stocks come to the rescue. Rebalance your portfolio with these three dividend stocks and enjoy steady income.
A mixed quarter and narrowed guidance didn't really please investors.
A mixed quarter and narrowed guidance didn't really please investors.
JNJ earnings call for the period ending March 31, 2024.
The healthcare giant's stock fell 2% following its first quarterly earning report of the year
On Tuesday, Johnson & Johnson (NYSE:JNJ) reported first-quarter adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64. The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21.39 billion. Operational growth was 3.9%, and adjusted operational growth was 4.0%. JNJ reported a net profit of $5.35 billion compared to a net loss of $(491) million a year ago, which included litigation charges of $6.9 billion. Innovative
JNJ stock results show that Johnson & Johnson beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Bank of America, Morgan Stanley, and Johnson & Johnson all reported earnings before the bell, with United Airlines coming later
Stocks eyed a broader comeback from a steep sell-off as investors digested results from Bank of America and other heavyweights.
Top S&P500 movers in Thursday's after hours session
Balancing Dividends and Fundamentals: The Case of JOHNSON & JOHNSON (NYSE:JNJ).